$235M Patent Award Spurs Teva Redo Request, GSK Fees Bid
One month after a Delaware federal jury found Teva Pharmaceuticals willfully infringed a patent tied to the hypertension drug Coreg and handed GlaxoSmithKline a $235 million verdict, Teva on Friday pushed...To view the full article, register now.
Already a subscriber? Click here to view full article